Vergoeding 2017-2021 voor ATC-subgroep J05A : Direct werkende antivirale middelen
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| J05AB Nucleosiden en nucleotiden (excl. reverse-transcr-remmers) | 5.810.800 | 4.390.500 | 4.572.700 | 5.912.800 | 4.678.000 |
| J05AD Fosfonzuurderivaten | 9.764 | 34.620 | 14.629 | 1.292 | 5.850 |
| J05AE Proteaseremmers | 14.786.900 | 11.719.100 | 7.098.600 | 3.408.600 | 1.935.500 |
| J05AF Nucleoside en nucleotide reverse-transcriptaseremmers | 15.768.400 | 7.970.200 | 4.726.600 | 4.977.100 | 4.495.700 |
| J05AG Niet-nucleoside reverse-transcriptaseremmers | 6.684.100 | 4.349.700 | 3.089.000 | 2.920.300 | 2.733.100 |
| J05AJ Integraseremmers | 17.659.500 | 19.952.500 | 20.985.000 | 19.297.900 | 17.314.400 |
| J05AP Antivirale middelen voor behandeling van hcv-infecties | 50.126.200 | 36.979.800 | 18.584.200 | 11.431.900 | 10.507.600 |
| J05AR Antivirale middelen voor hivinfectie combinatiepreparaten | 145.504.300 | 137.402.300 | 141.964.900 | 142.975.500 | 137.338.900 |
| J05AX Overige antivirale middelen | 842.580 | 766.600 | 1.122.700 | 1.761.800 | 2.451.000 |
| Totaal | 257.192.544 | 223.565.320 | 202.158.329 | 192.687.192 | 181.460.050 |